IPP Bureau
Biocon Academy conducts 8th Graduation Day
By IPP Bureau - December 19, 2023
Five batches across four programs of Biocon Academy participated in the graduation ceremony
CII recognized Cadila among Top 50 Innovative Companies in India
By IPP Bureau - December 19, 2023
Sanofi India appoints Himanshu Bakshi as GM - Consumer Healthcare Business
By IPP Bureau - December 19, 2023
His most recent stint was with Danone India as its Managing Director
Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease
By IPP Bureau - December 18, 2023
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Lupin receives tentative USFDA approval for Sitagliptin Tablets
By IPP Bureau - December 18, 2023
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Zydus receives final approval from the USFDA for Lacosamide Tablets
By IPP Bureau - December 18, 2023
Lacosamide is indicated to treat partial-onset seizures
Ami Organics inks agreement with Fermion for two additional APIs
By IPP Bureau - December 18, 2023
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries
By IPP Bureau - December 18, 2023
10+ emerging markets, Japan & ANZ transition in final phase
Briefs: Torrent Pharmaceuticals and Laurus Synthesis
By IPP Bureau - December 17, 2023
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Zydus receives final approval from the USFDA for Darunavir Tablets 600 mg and 800 mg
By IPP Bureau - December 17, 2023
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Zydus receives final USFDA approval for Cyclophosphamide Capsules USP, 25 mg and 50 mg
By IPP Bureau - December 17, 2023
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Fischer Chemic to acquire Time Medical Internaitonal Ventures India
By IPP Bureau - December 17, 2023
Fischer Chemic will make an entry into the growing market of diagnostic imaging industry with innovative and disruptive technologies
Biocon Biologics recognized as an Asia IP Elite for 2023
By IPP Bureau - December 17, 2023
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Lupin receives USFDA approval for Allopurinol Tablets
By IPP Bureau - December 17, 2023
The product will be manufactured at Lupin's Pithampur facility in India
Panacea Biotec launches EasyFourPol in India
By IPP Bureau - December 17, 2023
Receives registration of Valganciclovir powder for oral solution in Germany
